MedTrace Logo

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

NCT06922643 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-29

Study results available
· View outcomes & findings →

Summary

This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-naïve patients with Chronic Hepatitis C at Kien Giang General Hospital. The study aims to provide affordable treatment options while evaluating the virological response and side effects associated with the therapy

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Peginterferon Alfa-2A

180 mcg, subcutaneous injection, once weekly

DRUG

Ribavirin Oral Product

15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)

Sponsors & Collaborators

  • Nanogen Pharmaceutical Biotechnology Joint Stock Company

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-01
Primary Completion
2013-01-21
Completion
2013-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06922643 on ClinicalTrials.gov